Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Anavex Life Sciences Corp. (NASDAQ: AVXL).

Full DD Report for AVXL

You must become a subscriber to view this report.


Recent News from (NASDAQ: AVXL)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Anavex Life Sciences Corp's (AVXL) CEO Christopher Missling on Q1 2018 Results - Earnings Call Transcript
Anavex Life Sciences Corp (AVXL) Q1 2018 Earnings Conference Call May 10, 2018, 16:30 ET Executives Meggie Purcell - IR Christopher Missling - Chairman, President, CEO & Secretary Sandra Boenisch - Principal Financial Officer & Treasurer Analysts Robert LeBoyer - Ro...
Source: SeekingAlpha
Date: May, 11 2018 16:17
Anavex Life Sciences misses by $0.01
Anavex Life Sciences (NASDAQ: AVXL ): Q2 EPS of -$0.11 misses by $0.01 . Cash and equivalents of $25.7M Press Release More news on: Anavex Life Sciences Corp., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 10 2018 07:22
Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treat...
Source: GlobeNewswire
Date: May, 10 2018 07:00
Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
Conference Call and Webcast To be Held Thursday, May 10, 2018 at 4:30pm Eastern Time NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differ...
Source: GlobeNewswire
Date: May, 09 2018 07:00
Healthcare - Top 5 Gainers / Losers as of 11:00 AM (04/23/2018)
Gainers:  CHEK +14% . INSM +9% . EBIO +8% . AKCA +7% . AVXL +6% . More news on: Check-Cap Ltd., Insmed, Inc., Eleven Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 23 2018 11:03
Wired News - Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson's Disease Dementia
Stock Monitor: Aeterna Zentaris Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Anavex Life Sciences Corp. (NASDAQ: AVXL ) ("Anavex"). If you want access to this report all you need to do is sign up n...
Source: ACCESSWIRE IA
Date: April, 19 2018 07:20
Premarket Losers as of 9:05 am (4/17/2018)
LADR -9% . More news on: Ladder Capital Corp, Bellicum Pharmaceuticals, Anavex Life Sciences Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 17 2018 09:10
Anavex readies mid-stage study of lead candidate in PDD; shares ahead 2% premarket
Anavex Life Sciences (NASDAQ: AVXL ) is up  2%  premarket on average volume in response to its announcement that it plans to initiate a Phase 2 clinical trial evaluating lead candidate ANAVEX 2-73 in patients with Parkinson's Disease Dementia (PDD). The study should launch in H2....
Source: SeekingAlpha
Date: April, 17 2018 08:28
Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson's Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental dise...
Source: GlobeNewswire
Date: April, 17 2018 07:07

 


About Anavex Life Sciences Corp. (NASDAQ: AVXL)

Logo for Anavex Life Sciences Corp. (NASDAQ: AVXL)

Anavex is a pharmaceutical company engaged in the development of drug candidates.

 

Contact Information

 

 

Current Management

  • Christopher Missling / President, CEO, CFO
  • Christine Payne / IR
  • Sandra Boenisch / Principal Acct. Officer
  • Christopher Missling / Chairman
  • Elliot Favus /
  • Bernd Metzner /
  • Athanasios Skarpelos /
  • Steffen Thomas /

Current Share Structure

  • Market Cap: $119,012,014 - 03/20/2018
  • Authorized: 100,000,000 - 10/07/2015
  • Issue and Outstanding: 44,573,788 - 02/07/2018

 


Recent Filings from (NASDAQ: AVXL)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 08 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: AVXL)

Daily Technical Chart for (NASDAQ: AVXL)


Stay tuned for daily updates and more on (NASDAQ: AVXL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AVXL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVXL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of AVXL and does not buy, sell, or trade any shares of AVXL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/